{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sequential+Therapy&page=14",
    "query": {
      "intervention": "Sequential Therapy",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 716,
    "total_pages": 72,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sequential+Therapy&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sequential+Therapy&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T19:26:30.016Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06441331",
      "title": "Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Somatostatin Receptor Positive",
        "NETs",
        "Lymphoma",
        "Solid Tumor",
        "CNS Tumors",
        "Rhabdomyosarcoma",
        "Peripheral Primitive Neuroectodermal Tumor",
        "GIST"
      ],
      "interventions": [
        {
          "name": "Lutetium Lu 177-Edotreotide",
          "type": "DRUG"
        },
        {
          "name": "Amino Acid Solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ITM Solucin GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "24 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "24 Months to 18 Years"
      },
      "enrollment_count": 20,
      "start_date": "2025-09-26",
      "completion_date": "2034-04",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-10-27T19:26:30.016Z",
      "location_count": 5,
      "location_summary": "Palo Alto, California • San Francisco, California • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06441331"
    },
    {
      "nct_id": "NCT06520345",
      "title": "The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "177Lu-TLX591",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Telix Pharmaceuticals (Innovations) Pty Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 520,
      "start_date": "2024-07-26",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-10-27T19:26:30.016Z",
      "location_count": 9,
      "location_summary": "Orange, California • Miami, Florida • Glen Burnie, Maryland + 6 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Glen Burnie",
          "state": "Maryland"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06520345"
    },
    {
      "nct_id": "NCT03035630",
      "title": "Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clear-cell Renal Cell Carcinoma",
        "RCC",
        "Kidney Cancer",
        "Clear-cell Kidney Carcinoma"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Guru Sonpavde",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2017-05-23",
      "completion_date": "2020-12",
      "has_results": false,
      "last_update_posted_date": "2022-02-15",
      "last_synced_at": "2026-10-27T19:26:30.016Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03035630"
    },
    {
      "nct_id": "NCT06748222",
      "title": "E-Mindfulness Approaches for Living After Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer",
        "Depression"
      ],
      "interventions": [
        {
          "name": "Mindfulness (MAPs) Live Online",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Mindfulness (MAPs) Digital App",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Meditation Only Control Group",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 402,
      "start_date": "2025-06-27",
      "completion_date": "2030-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-10-27T19:26:30.016Z",
      "location_count": 381,
      "location_summary": "Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 317 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06748222"
    },
    {
      "nct_id": "NCT05839951",
      "title": "An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Metastatic Colorectal Cancer (mCRC)"
      ],
      "interventions": [
        {
          "name": "Regorafenib (BAY73-4506, Stivarga®)",
          "type": "DRUG"
        },
        {
          "name": "TAS-102 (trifluridine and tipiracil, Lonsurf®)",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 818,
      "start_date": "2023-04-24",
      "completion_date": "2025-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-10-27T19:26:30.016Z",
      "location_count": 1,
      "location_summary": "Whippany, New Jersey",
      "locations": [
        {
          "city": "Whippany",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05839951"
    },
    {
      "nct_id": "NCT06980480",
      "title": "A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Secondary Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "IGI, 10%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 183,
      "start_date": "2026-01-14",
      "completion_date": "2028-09-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-27T19:26:30.016Z",
      "location_count": 7,
      "location_summary": "Mobile, Alabama • Orange, California • Westwood, Kansas + 4 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06980480"
    },
    {
      "nct_id": "NCT07031739",
      "title": "Sequential Multiple Assignment Randomized Trial to Reduce Food Insecurity",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Uncontrolled Hypertension"
      ],
      "interventions": [
        {
          "name": "Resource information",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Community Health Worker (CHW) assistance",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Medically-tailored Meals (MTM)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 224,
      "start_date": "2025-08-18",
      "completion_date": "2030-02",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-27T19:26:30.016Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07031739"
    },
    {
      "nct_id": "NCT04296942",
      "title": "BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Triple Negative Breast Cancer",
        "HER2+ Breast Cancer",
        "Hormone Receptor Negative Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Brachyury-TRICOM",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Entinostat",
          "type": "DRUG"
        },
        {
          "name": "M7824",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ado-trastuzumab emtansine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-05-04",
      "completion_date": "2021-10-22",
      "has_results": true,
      "last_update_posted_date": "2022-01-11",
      "last_synced_at": "2026-10-27T19:26:30.016Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04296942"
    },
    {
      "nct_id": "NCT00021528",
      "title": "Sequenced Treatment Alternatives to Relieve Depression (STAR*D)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depression"
      ],
      "interventions": [
        {
          "name": "citalopram",
          "type": "DRUG"
        },
        {
          "name": "BuproprionSR",
          "type": "DRUG"
        },
        {
          "name": "buspirone",
          "type": "DRUG"
        },
        {
          "name": "Lithium",
          "type": "DRUG"
        },
        {
          "name": "mirtazapine",
          "type": "DRUG"
        },
        {
          "name": "nortriptyline",
          "type": "DRUG"
        },
        {
          "name": "sertraline",
          "type": "DRUG"
        },
        {
          "name": "tranylcypromine",
          "type": "DRUG"
        },
        {
          "name": "VenlafaxineXR",
          "type": "DRUG"
        },
        {
          "name": "Cognitive Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "T3 (Triiodothyronine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 4000,
      "start_date": "2001-07",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2009-09-25",
      "last_synced_at": "2026-10-27T19:26:30.016Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Chula Vista, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Harbor City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00021528"
    },
    {
      "nct_id": "NCT03904693",
      "title": "Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)"
      ],
      "interventions": [
        {
          "name": "FDC macitentan/tadalafil",
          "type": "DRUG"
        },
        {
          "name": "Macitentan 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Tadalafil 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo FDC",
          "type": "DRUG"
        },
        {
          "name": "Placebo macitentan",
          "type": "DRUG"
        },
        {
          "name": "Placebo tadalafil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 187,
      "start_date": "2019-07-29",
      "completion_date": "2024-09-27",
      "has_results": true,
      "last_update_posted_date": "2025-12-19",
      "last_synced_at": "2026-10-27T19:26:30.016Z",
      "location_count": 26,
      "location_summary": "Fullerton, California • Los Angeles, California • Atlanta, Georgia + 22 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03904693"
    }
  ]
}